Daily intranasal oxytocin for 4 weeks doubled social interaction time in Shank3-knockout autism model mice, reduced repetitive behaviors by 30%, and these effects persisted for 4 weeks after treatment ended — though a 10% increase in social disinterest suggests complex behavioral effects.
2x social interaction timeShank3-knockout autism model mice treated with intranasal oxytocin spent twice as much time interacting socially, starting from just 2 weeks of daily treatment
What the researchers found
Daily intranasal oxytocin (0.8 IU/kg for 4 weeks): 2x more social interaction time from week 2. 50% reduced explorative behavior at 4 weeks. 30% reduction in repetitive behavior persisting 4 weeks post-treatment. Effects lasted 4 weeks after treatment ended. However, ~10% increase in social disinterest also observed.
Why it matters
ASD core symptoms (social deficits, repetitive behaviors) have no approved pharmacological treatment. Oxytocin has long been a candidate, but clinical trial results have been ambiguous. This study in a genetic model shows clear, lasting benefits — but also reveals concerning social ambivalence that may explain mixed clinical results and demands careful investigation.
The numbers in context
Oxytocin is a neuropeptide. Delivered intranasally in a genetic ASD mouse model.
How the study worked
Animal study using Shank3-/- adult mice (genetic autism model). Daily intranasal oxytocin (0.8 IU/kg) for 4 weeks. Behavioral testing during treatment (weeks 2, 4) and post-treatment (4 weeks after cessation). Outcomes: social interaction time, explorative behavior, repetitive behaviors, social disinterest. Published in Molecular Psychiatry.
Who was studied
Mice with genetic model of autism spectrum disorder
What this study cannot tell us
Mouse model — Shank3 knockout represents only a subset of ASD. Behavioral tests may not fully capture human social complexity. The 10% increase in social disinterest is concerning and poorly understood. No dose-response or long-term safety data. Intranasal delivery in mice differs from human nasal anatomy.
How to read the evidence
Rated preliminary: well-designed genetic mouse model study published in a high-impact journal (Molecular Psychiatry), but animal behavioral data doesn't directly predict human ASD treatment outcomes.
When this study was published
Published in 2024. Contributes to the ongoing debate about oxytocin's potential as an ASD treatment.
The bigger picture
The persistence of oxytocin's effects for 4 weeks after stopping treatment suggests it may produce lasting changes in social brain circuits, not just acute pharmacological effects. This has important implications for clinical trial design — intermittent oxytocin treatment might be sufficient. However, the social ambivalence finding adds nuance to the simplified narrative of oxytocin as a purely 'prosocial' neuropeptide.
Questions still open
- Why does oxytocin simultaneously increase social interaction and social disinterest — what drives this ambivalence?
- Could intermittent oxytocin dosing (e.g., weekly) capture the lasting benefits while reducing the ambivalence?
- Do the sustained post-treatment effects reflect epigenetic changes in social brain circuits?
Common questions
Can oxytocin help with autism?
Why haven't oxytocin treatments for autism worked consistently in clinical trials?
Read the original research
Intranasal oxytocin in a genetic animal model of autism.
Molecular psychiatry, 29(2), 342-347
Citation
Szabó, Jakub; Mlynár, Matúš; Feješ, Andrej; Renczés, Emese; Borbélyová, Veronika; Ostatníková, Daniela; Celec, Peter. (2024). Intranasal oxytocin in a genetic animal model of autism.. Molecular psychiatry, 29(2), 342-347. https://doi.org/10.1038/s41380-023-02330-6